BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 9053858)

  • 21. Felis catus papillomavirus type-2 E6 binds to E6AP, promotes E6AP/p53 binding and enhances p53 proteasomal degradation.
    Altamura G; Power K; Martano M; Degli Uberti B; Galiero G; De Luca G; Maiolino P; Borzacchiello G
    Sci Rep; 2018 Dec; 8(1):17529. PubMed ID: 30510267
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Binding of human papillomavirus 16 E6 to p53 and E6AP is impaired by monoclonal antibodies directed against the second zinc-binding domain of E6.
    Lagrange M; Charbonnier S; Orfanoudakis G; Robinson P; Zanier K; Masson M; Lutz Y; Trave G; Weiss E; Deryckere F
    J Gen Virol; 2005 Apr; 86(Pt 4):1001-1007. PubMed ID: 15784893
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Surface plasmon resonance imaging protein arrays for analysis of triple protein interactions of HPV, E6, E6AP, and p53.
    Ro HS; Koh BH; Jung SO; Park HK; Shin YB; Kim MG; Chung BH
    Proteomics; 2006 Apr; 6(7):2108-11. PubMed ID: 16493710
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Adenovirus-mediated transfer of human papillomavirus 16 E6/E7 antisense RNA and induction of apoptosis in cervical cancer.
    Hamada K; Shirakawa T; Gotoh A; Roth JA; Follen M
    Gynecol Oncol; 2006 Dec; 103(3):820-30. PubMed ID: 16908054
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Identification of MicroRNAs That Stabilize p53 in Human Papillomavirus-Positive Cancer Cells.
    Martínez-Noël G; Szajner P; Kramer RE; Boyland KA; Sheikh A; Smith JA; Howley PM
    J Virol; 2022 Feb; 96(4):e0186521. PubMed ID: 34878887
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Identification of E6AP-independent degradation targets of HPV E6.
    Vats A; Thatte J; Banks L
    J Gen Virol; 2019 Dec; 100(12):1674-1679. PubMed ID: 31609195
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The role of TP53 in Cervical carcinogenesis.
    Tommasino M; Accardi R; Caldeira S; Dong W; Malanchi I; Smet A; Zehbe I
    Hum Mutat; 2003 Mar; 21(3):307-12. PubMed ID: 12619117
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Alternatively spliced HPV-18 E6* protein inhibits E6 mediated degradation of p53 and suppresses transformed cell growth.
    Pim D; Massimi P; Banks L
    Oncogene; 1997 Jul; 15(3):257-64. PubMed ID: 9233760
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Requirement of E6AP and the features of human papillomavirus E6 necessary to support degradation of p53.
    Cooper B; Schneider S; Bohl J; Jiang Yh; Beaudet A; Vande Pol S
    Virology; 2003 Feb; 306(1):87-99. PubMed ID: 12620801
    [TBL] [Abstract][Full Text] [Related]  

  • 30. HPV16 E6 confers p53-dependent and p53-independent phenotypes in the epidermis of mice deficient for E6AP.
    Shai A; Nguyen ML; Wagstaff J; Jiang YH; Lambert PF
    Oncogene; 2007 May; 26(23):3321-8. PubMed ID: 17130828
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The global transcriptional effects of the human papillomavirus E6 protein in cervical carcinoma cell lines are mediated by the E6AP ubiquitin ligase.
    Kelley ML; Keiger KE; Lee CJ; Huibregtse JM
    J Virol; 2005 Mar; 79(6):3737-47. PubMed ID: 15731267
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cellular targets of the oncoproteins encoded by the cancer associated human papillomaviruses.
    Howley PM; Münger K; Romanczuk H; Scheffner M; Huibregtse JM
    Princess Takamatsu Symp; 1991; 22():239-48. PubMed ID: 1668886
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Stepwise multipolyubiquitination of p53 by the E6AP-E6 ubiquitin ligase complex.
    Masuda Y; Saeki Y; Arai N; Kawai H; Kukimoto I; Tanaka K; Masutani C
    J Biol Chem; 2019 Oct; 294(41):14860-14875. PubMed ID: 31492752
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pitx2a binds to human papillomavirus type 18 E6 protein and inhibits E6-mediated P53 degradation in HeLa cells.
    Wei Q
    J Biol Chem; 2005 Nov; 280(45):37790-7. PubMed ID: 16129685
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparison of human papillomavirus type 18 (HPV-18) E6-mediated degradation of p53 in vitro and in vivo reveals significant differences based on p53 structure and cell type but little difference with respect to mutants of HPV-18 E6.
    Gardiol D; Banks L
    J Gen Virol; 1998 Aug; 79 ( Pt 8)():1963-70. PubMed ID: 9714244
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Specific apoptosis induction in human papillomavirus-positive cervical carcinoma cells by photodynamic antisense regulation.
    Yamayoshi A; Kato K; Suga S; Ichinoe A; Arima T; Matsuda T; Kato H; Murakami A; Wake N
    Oligonucleotides; 2007; 17(1):66-79. PubMed ID: 17461764
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Ubiquitination of the HPV Oncoprotein E6 Is Critical for E6/E6AP-Mediated p53 Degradation.
    Li S; Hong X; Wei Z; Xie M; Li W; Liu G; Guo H; Yang J; Wei W; Zhang S
    Front Microbiol; 2019; 10():2483. PubMed ID: 31749782
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Association of E6AP (UBE3A) with human papillomavirus type 11 E6 protein.
    Brimer N; Lyons C; Vande Pol SB
    Virology; 2007 Feb; 358(2):303-10. PubMed ID: 17023019
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A ubiquitin variant-based affinity approach selectively identifies substrates of the ubiquitin ligase E6AP in complex with HPV-11 E6 or HPV-16 E6.
    Ebner FA; Sailer C; Eichbichler D; Jansen J; Sladewska-Marquardt A; Stengel F; Scheffner M
    J Biol Chem; 2020 Oct; 295(44):15070-15082. PubMed ID: 32855237
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Induction of apoptosis by p53 is independent of its oligomeric state and can be abolished by HPV-18 E6 through ubiquitin mediated degradation.
    Thomas M; Matlashewski G; Pim D; Banks L
    Oncogene; 1996 Jul; 13(2):265-73. PubMed ID: 8710365
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.